Stockreport

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics, Inc.  (CATX) 
PDF Updated interim results with an additional ~13 weeks of follow-up since the prior update[212Pb]VMT-a-NET continues to be well-tolerated Updated efficacy analysis suggest [Read more]